X.e

Autoimmunity - Autoimmune conditions

Corresponds to circulating autoantibodies (ANA, anti-dsDNA, multispecific ANCA). Titers can be very high and/or multispecific and tend to diminish in a few weeks or months upon drug discontinuance. Autoimmunity can be asymptomatic or is with various clinical presentations including pulmonary vascultis or hemorrhage (PMID 20015613). See also under patterns IIIa, IIIb, IIId, Vd, VId, and  Xb, d, h, j, m, s, x, y, ac, ah, am, ao, aw, ax, ay

Last update : 25/04/2018
 

Causative drugs

16

Breast implants/prosthesis

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.al I - Interstitial/parenchymal lung disease
I.al - Silicone pneumonitis - 'Silicone lung'
I.am I - Interstitial/parenchymal lung disease
I.am - Siliconoma
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.v V - Pleural and/or pericardial involvement
V.v - Silicone pleural effusion
V.w V - Pleural and/or pericardial involvement
V.w - Silicone pleural nodules - Pleural siliconomas
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.h X - Systemic conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.q X - Systemic conditions, syndromes and reactions
X.q - Systemic inflammatory response
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.ad X - Systemic conditions, syndromes and reactions
X.ad - Skin purpura, ecchymoses or necrosis
XIII.f XIII - Neoplastic conditions
XIII.f - Fibromatosis of the chest wall
XIII.h XIII - Neoplastic conditions
XIII.h - Pulmonary nodular lymphoid hyperplasia
XIII.i XIII - Neoplastic conditions
XIII.i - Breast implant-associated anaplastic large cell lymphoma
XV.bn XV - Pulmonary pathology
XV.bn - Path: Silicone in lung tissue, pulmonary vasculature or pleura
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.av XVI - Imaging
XVI.av - Imaging: Displacement/migration of breast implant
XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy
XVIII.c XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.c - Eye catcher: A displaced breast implant
1

Etanercept

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.q I - Interstitial/parenchymal lung disease
I.q - Nodules in lung parenchyma (a.k.a. nodulosis)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apneas
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.ar X - Systemic conditions, syndromes and reactions
X.ar - Relapse/flare/onset of Crohn's disease
XI.ad XI - Miscellaneous
XI.ad - Granulomas on tattoo edges
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.ba XV - Pulmonary pathology
XV.ba - Path: Granulomatous lymphadenopathy
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XVII.ab XVII - Infections & related conditions
XVII.ab - Protozoan infection (incl. leishmaniasis)
3

Hydralazine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.b III - Pulmonary hemorrhage
III.b - Pneumorenal syndrome
III.d III - Pulmonary hemorrhage
III.d - Alveolar hemorrhage, diffuse, ANCA-positive or related
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (may cause acute chest pain (see also under XIc)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.h VIII - Upper, central, large airway involvement
VIII.h - Vocal cord dysfunction, adduction, closure
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.o X - Systemic conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet)
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.ak X - Systemic conditions, syndromes and reactions
X.ak - Dual MPO-/PR3-ANCA systemic disease/vasculitis
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.k XII - Cardiovascular involvement / toxicity
XII.k - Pericardial thickening - Constrictive pericarditis
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
2

Immune checkpoint inhibitors (ICPI) - ICPI combinatorial therapy

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.c X - Systemic conditions, syndromes and reactions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.am X - Systemic conditions, syndromes and reactions
X.am - Immune-related adverse effect/toxicity
X.aw X - Systemic conditions, syndromes and reactions
X.aw - Connective tissue disease
XI.y XI - Miscellaneous
XI.y - Adrenal suppression
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XIX.a XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
2

Infliximab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.h X - Systemic conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.ah X - Systemic conditions, syndromes and reactions
X.ah - Granulomatosis with polyangiitis (w/wo ANCA) or flare of
X.ar X - Systemic conditions, syndromes and reactions
X.ar - Relapse/flare/onset of Crohn's disease
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass shadowing/opacities (GGO)
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XVII.n XVII - Infections & related conditions
XVII.n - Legionella pneumophila pneumonia
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XVII.y XVII - Infections & related conditions
XVII.y - Cryptococcus neoformans pulmonary infection
XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation)
XVII.ac XVII - Infections & related conditions
XVII.ac - Actinomycosis
1

Ipilimumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemidiaphragmatic paralysis
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis (may cause neuromuscular ARF)
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.l X - Systemic conditions, syndromes and reactions
X.l - Systemic granulomatosis other than Xk
X.o X - Systemic conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet)
X.am X - Systemic conditions, syndromes and reactions
X.am - Immune-related adverse effect/toxicity
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
1

Minocycline

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.aj I - Interstitial/parenchymal lung disease
I.aj - Shrinking lung syndrome
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.o X - Systemic conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet)
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.v X - Systemic conditions, syndromes and reactions
X.v - Systemic eosinophilic syndrome w/wo vasculitis (see also Xa)
X.aj X - Systemic conditions, syndromes and reactions
X.aj - Polyarteritis nodosa-like condition
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi)
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.as XII - Cardiovascular involvement / toxicity
XII.as - Giant cell myocarditis
XIX.b XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.c XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
2

Nitrofurantoin

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.j II - Pulmonary edema - ARDS - Acute respiratory failure
II.j - Transient pulmonary opacities
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (may cause acute chest pain (see also under XIc)
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
VIII.b VIII - Upper, central, large airway involvement
VIII.b - Hematoma causing upper airway obstruction
IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi)
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.h XV - Pulmonary pathology
XV.h - Path: Fibrotic NSIP pattern
XV.j XV - Pulmonary pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XV.k XV - Pulmonary pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XV.x XV - Pulmonary pathology
XV.x - Path: Acute or subacute bronchiolitis (see also IVc, IVi)
XV.ac XV - Pulmonary pathology
XV.ac - Path: Pulmonary vasculitis other than capillaritis
XV.af XV - Pulmonary pathology
XV.af - Path: Granulomatous pulmonary vasculitis
XV.bi XV - Pulmonary pathology
XV.bi - Path: Giant-cell interstitial pneumonia (GIP)-pattern
XV.bl XV - Pulmonary pathology
XV.bl - Path: Resolving alveolar damage
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass shadowing/opacities (GGO)
XVI.f XVI - Imaging
XVI.f - Imaging: Bibasilar opacities/shadowing
XVI.l XVI - Imaging
XVI.l - Imaging: Peribronchovascular areas of consolidation
2

Oil, paraffin, lipids (mineral- or other), aspirated

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.w IV - Airway involvement
IV.w - Plugs/casts in the airways
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XV.h XV - Pulmonary pathology
XV.h - Path: Fibrotic NSIP pattern
XV.p XV - Pulmonary pathology
XV.p - Path: Exogenous lipoid pneumonia
XV.q XV - Pulmonary pathology
XV.q - Path: Foreign body deposits/reaction
XVI.a XVI - Imaging
XVI.a - Imaging: Diffuse haze
XVI.f XVI - Imaging
XVI.f - Imaging: Bibasilar opacities/shadowing
XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.n XVI - Imaging
XVI.n - Imaging: Intralobular septal thickening - Crazy paving
XVI.r XVI - Imaging
XVI.r - Imaging: An area or areas of involvement with low attenuation numbers
XVI.z XVI - Imaging
XVI.z - Imaging: A large nodule or mass
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.az XVI - Imaging
XVI.az - Imaging: Solitary pulmonary nodule
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XIX.h XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.h - BAL: Lipid vacuoles in BAL alveolar macrophages
XIX.j XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.j - BAL: Free exogenous lipids in supernatant
1

Penicillamine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.b III - Pulmonary hemorrhage
III.b - Pneumorenal syndrome
III.d III - Pulmonary hemorrhage
III.d - Alveolar hemorrhage, diffuse, ANCA-positive or related
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis (may cause neuromuscular ARF)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.ac X - Systemic conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of
XI.t XI - Miscellaneous
XI.t - Yellow nail syndrome
XV.z XV - Pulmonary pathology
XV.z - Path: Chronic obliterative broncholitis (see also IVc, IVn)
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
1

Propylthiouracil (PTU)

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.b III - Pulmonary hemorrhage
III.b - Pneumorenal syndrome
III.d III - Pulmonary hemorrhage
III.d - Alveolar hemorrhage, diffuse, ANCA-positive or related
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.r IV - Airway involvement
IV.r - Airway pigmentation (black, bluish, petechial)
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
V.u V - Pleural and/or pericardial involvement
V.u - Eosinophilic pleuritis
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.x X - Systemic conditions, syndromes and reactions
X.x - Subclinical ANCA positivity
X.ak X - Systemic conditions, syndromes and reactions
X.ak - Dual MPO-/PR3-ANCA systemic disease/vasculitis
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.h XV - Pulmonary pathology
XV.h - Path: Fibrotic NSIP pattern
XV.an XV - Pulmonary pathology
XV.an - Path: Eosinophilic pleuritis
2

TNF-alpha antagonists/inhibitors

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.q I - Interstitial/parenchymal lung disease
I.q - Nodules in lung parenchyma (a.k.a. nodulosis)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.d III - Pulmonary hemorrhage
III.d - Alveolar hemorrhage, diffuse, ANCA-positive or related
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apneas
IX.t IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.t - CNS involvement/dysfunction
X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.p X - Systemic conditions, syndromes and reactions
X.p - Serum sickness-like reaction
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.x X - Systemic conditions, syndromes and reactions
X.x - Subclinical ANCA positivity
X.ae X - Systemic conditions, syndromes and reactions
X.ae - Antisynthetase antibodies (ASA)-ASA syndrome
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection
XVII.n XVII - Infections & related conditions
XVII.n - Legionella pneumophila pneumonia
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XVII.y XVII - Infections & related conditions
XVII.y - Cryptococcus neoformans pulmonary infection
XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation)
XVII.ab XVII - Infections & related conditions
XVII.ab - Protozoan infection (incl. leishmaniasis)
3